Congress trades
Abiomed, Inc. (ABMD)
About Abiomed, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Michael Minogue
- Employees
- 2,003
- Listed since
- Jul 29, 1987
- Market value
- $17.2B
- Price to earnings
- 127.0
- Earnings per share
- $3.00
- Dividend yield
- -
Earnings
6 reported quarters · next on Feb 2, 2023| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2023reported Nov 1, 2022 | $1.30 | $1.04 | $265.9M | n/a | EPS beatRevenue n/a |
| Q1 FY2023reported Aug 4, 2022 | $1.25 | $1.06 | $277.1M | n/a | EPS beatRevenue n/a |
| Apr 28, 2022 | $1.16 | $1.09 | $269.9M | $252.5M | EPS beatRevenue beat |
| Q3 FY2022reported Feb 3, 2022 | $1.13 | $0.95 | $261.2M | $266.8M | EPS beatRevenue miss |
| Q2 FY2022reported Oct 28, 2021 | $1.03 | $0.97 | $248.1M | $251.6M | EPS beatRevenue in line |
| Q1 FY2022reported Aug 4, 2021 | $1.41 | $1.05 | $252.6M | $252.6M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in ABMD
20 disclosures of 33 on record · median 28d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +2.0%S&P +4.1% · vs S&P 500 -2.1% | Nov 3, 2022 | Dec 6, 2022 | 33d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +44.2%S&P -2.2% · vs S&P 500 +46.3% | Sep 14, 2022 | Oct 16, 2022 | 32d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +65.8%S&P +5.0% · vs S&P 500 +60.8% | Jun 17, 2022 | Jul 7, 2022 | 20d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +69.6%S&P +5.3% · vs S&P 500 +64.3% | Jun 16, 2022 | Jul 7, 2022 | 21d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +52.9%S&P -2.7% · vs S&P 500 +55.6% | May 23, 2022 | Jun 10, 2022 | 18d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +60.3%S&P -3.2% · vs S&P 500 +63.6% | May 10, 2022 | Jun 10, 2022 | 31d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +27.1%S&P -12.2% · vs S&P 500 +39.4% | Apr 11, 2022 | May 6, 2022 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +31.2%S&P -12.1% · vs S&P 500 +43.3% | Feb 14, 2022 | Mar 8, 2022 | 22d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +19.4%S&P -17.8% · vs S&P 500 +37.2% | Jan 11, 2022 | Feb 8, 2022 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +25.1%S&P -11.9% · vs S&P 500 +37.0% | Jan 21, 2022 | Feb 8, 2022 | 18d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +17.5%S&P +3.3% · vs S&P 500 +14.3% | Dec 31, 2020 | Jan 11, 2021 | 11d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +25.3%S&P +5.1% · vs S&P 500 +20.3% | Dec 23, 2020 | Jan 11, 2021 | 19d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +29.2%S&P +16.0% · vs S&P 500 +13.2% | Aug 11, 2020 | Sep 14, 2020 | 34d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | +51.9%S&P +21.0% · vs S&P 500 +30.9% | Jun 10, 2020 | Jul 17, 2020 | 37d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +138.0%S&P +38.8% · vs S&P 500 +99.2% | Apr 9, 2020 | May 13, 2020 | 34d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +149.4%S&P +45.7% · vs S&P 500 +103.7% | Apr 7, 2020 | May 13, 2020 | 36d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $15,001 - $50,000 | +104.5%S&P +20.0% · vs S&P 500 +84.5% | Jan 31, 2020 | Feb 18, 2020 | 18d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +101.5%S&P +18.6% · vs S&P 500 +82.9% | Jan 10, 2020 | Feb 10, 2020 | 31d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +112.0%S&P +23.2% · vs S&P 500 +88.8% | Dec 10, 2019 | Jan 6, 2020 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +43.8%S&P +30.8% · vs S&P 500 +13.0% | Jul 1, 2019 | Aug 6, 2019 | 36d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 9, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded ABMD?
Ro Khanna, Josh Gottheimer, Gilbert Ray Cisneros, Jr. disclosed ABMD transactions in the filings shown here.
How quickly are ABMD trades disclosed?
Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.